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OBJECTIVES: To examine associations between sarcope-
nia, obesity, and sarcopenic obesity and risk of cardiovas-
cular disease (CVD) and all-cause mortality in older men.
DESIGN: Prospective cohort study.
SETTING: British Regional Heart Study.
PARTICIPANTS: Men aged 60–79 years (n = 4,252).
MEASUREMENTS: Baseline waist circumference (WC)
and midarm muscle circumference (MAMC) measurements
were used to classify participants into four groups: sarco-
penic, obese, sarcopenic obese, or optimal WC and
MAMC. The cohort was followed for a mean of
11.3 years for CVD and all-cause mortality. Cox regres-
sion analyses assessed associations between sarcopenic
obesity groups and all-cause mortality, CVD mortality,
CVD events, and coronary heart disease (CHD) events.
RESULTS: There were 1,314 deaths, 518 CVD deaths,
852 CVD events, and 458 CHD events during follow-up.
All-cause mortality risk was significantly greater in sarco-
penic (HR = 1.41, 95% CI = 1.22–1.63) and obese
(HR = 1.21, 95% CI = 1.03–1.42) men than in the opti-
mal reference group, with the highest risk in sarcopenic
obese (HR = 1.72, 95% CI = 1.35–2.18), after adjustment
for lifestyle characteristics. Risk of CVD mortality was sig-
nificantly greater in sarcopenic and obese but not sarcope-
nic obese men. No association was seen between
sarcopenic obesity groups and CHD or CVD events.
CONCLUSION: Sarcopenia and central adiposity were
associated with greater cardiovascular mortality and all-
cause mortality. Sarcopenic obese men had the highest risk
of all-cause mortality but not CVD mortality. Efforts to
promote healthy aging should focus on preventing obesity
and maintaining muscle mass. J Am Geriatr Soc 62:253–
260, 2014.
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Important changes to body composition occur with age;although body weight and body mass index (BMI) may
remain relatively unchanged, typically visceral fat
increases and muscle mass decreases.1 Sarcopenic obesity
refers to the age-associated loss of muscle mass coupled
with high levels of adiposity, but no consensus definition
of sarcopenic obesity exists.2–4 Measuring the effect of
obesity in elderly adults may be limited when using BMI,
because it combines fat and muscle mass,5 but abdominal
obesity is an established risk factor for cardiovascular
disease (CVD) and all-cause mortality. A meta-analysis
of 29 elderly cohorts including men and women aged
65–74 years showed a significant positive association
between waist circumference (WC) and all-cause and
CVD mortality risk that was consistent across BMI
categories.6
Prospective studies have also shown consistent associa-
tions between low muscle mass and mortality risk,7–11
although the association between sarcopenia and CVD risk
is not well established, and the combined effects of sarco-
penia and obesity on CVD and all-cause mortality have
not been well studied. A recent review found that the
majority of studies examining associations between sarco-
penic obesity and health outcomes have focused on func-
tional capacity or disability or have been cross-sectional.12
Sarcopenic obesity has been linked prospectively to greater
risk of all-cause mortality in disease-specific popula-
tions,13,14 but few studies have prospectively examined
the effect of sarcopenic obesity on CVD outcomes and
mortality. A large longitudinal study, the Cardiovascular
Health Study, found that sarcopenic obesity classified
using muscle strength was modestly associated with CVD
risk but that sarcopenic obesity classified using muscle
mass was not associated with CVD risk.15
A previous report from this cohort examined anthro-
pometric indexes of body composition and found that high
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WC and low muscle mass, as measured using midarm
muscle circumference (MAMC), were associated with all-
cause mortality,10 but the concept of sarcopenic obesity
was not examined, and the influence of sarcopenia (low
muscle mass) on CVD risk was not explored. The objective
of this study was to prospectively examine associations
between sarcopenia, obesity, and sarcopenic obesity,
defined using WC and MAMC measurements, and risk of
CVD events and all-cause mortality in a large, nationally
representative, population-based study of older British
men. A secondary objective was to examine associations
between sarcopenia, obesity, and sarcopenic obesity
defined using alternative measurements, fat mass (FM) and
fat-free mass (FFM), and risk of CVD events and all-cause
mortality.
METHODS
Participants and Study Design
The British Regional Heart Study is a prospective study in
a socioeconomically and geographically representative
sample of 7,735 British men from 24 towns in Great
Britain.16 This cohort of predominantly white Europeans
(>99%) was initially examined in 1978–1980. Twenty
years later, in 1998–2000, 4,252 men (77% of survivors),
then aged 60–79, attended a physical examination,
provided a fasting blood sample, and completed a
questionnaire.17 This study used data from the 20-year
re-examination and follow-up data on CVD and mortality
until 2010. Participants provided written informed consent
in accordance with the Declaration of Helsinki. Ethical
approval was obtained from all relevant local research eth-
ics committees.
Anthropometric Measurements and Sarcopenic Obesity
Definition
Anthropometric measurements at re-examination included
height, weight, WC, midupper arm circumference, triceps
skinfold thickness, FM, and FFM as described
previously.10 Participants were also asked to report
whether their weight had changed in the previous 3 years,
and a dichotomous weight loss variable was created
(yes = weight loss; no = no change, gain, or fluctuation).
WC was chosen to indicate abdominal obesity instead of a
measure of total obesity. Obesity was defined using an
established sex-specific cut-point (WC > 102 cm).18
MAMC (cm) was used as a marker of muscle mass and
was calculated as midupper arm circumference (cm) –
0.3142 9 triceps skinfold thickness (mm).19 MAMC has
been shown to correlate strongly with more-accurate mea-
sures of lean mass measured using dual energy X-ray
absorptiometry.20 Because no consensus definition of sar-
copenia has yet been adopted,4 a standard statistical
approach was used to define sarcopenia: participants in
the lowest two-fifths of the MAMC distribution. Partici-
pants were categorized into four nonoverlapping sarcope-
nic obesity groups: optimal (WC ≤102 cm,
MAMC > 25.9 cm), sarcopenic (WC ≤102 cm, MAMC
≤25.9 cm), obese (WC > 102 cm, MAMC > 25.9 cm), or
sarcopenic obese (WC > 102 cm, MAMC ≤25.9 cm).
Alternative Sarcopenic Obesity Definition
For comparative purposes, an alternative sarcopenic obes-
ity classification was created using FFM and FM measure-
ments, determined using bioelectrical impedance analysis
(BIA) on fasting participants (Bodystat 500, Bodystat Ltd,
Douglas, UK). FFM was calculated using the Deurenberg
equation,21 and FM was calculated as body weight (kg) –
FFM (kg). FFM and FM measures were normalized for
height by dividing by height (m2) to give a FFM index
(FFMI) and a FM index (FMI) in kg/m2.22 For comparabil-
ity with the MAMC and WC categories, participants in
the lowest two-fifths of the FFMI were classified as sarco-
penic (≤16.7 kg/m2), and those above the percentile point
of FMI corresponding to the WC obesity cutoff (28.7th
percentile) were classified as obese (>11.1 kg/m2).
CVD Risk Factors
Cigarette smoking, physical activity, alcohol intake, and
occupational social class were self-reported in a question-
naire, and blood pressure, blood lipids, and lung function
(forced expiratory volume in 1 second (FEV1)) were mea-
sured as described previously.10,16,23,24 Men were classified
into four cigarette smoking groups (never smoked, long-
term ex-smoker, recent ex-smoker, current smoker). A
physical activity score was derived on the basis of physical
activity frequency and type, and men were grouped into
six categories: inactive, occasional (regular walking or rec-
reational activity only), light (more-frequent recreational
activities, sporting exercise less than once a week, or regu-
lar walking plus some recreational activity), moderate
(cycling, very frequent weekend recreational activities plus
regular walking, or sporting activity once a week), moder-
ately vigorous (sporting activity at least once a week or
frequent cycling, plus frequent recreational activities or
walking, or frequent sporting activities only), vigorous
(very frequent sporting exercise or frequent sporting exer-
cise plus other recreational activities). Validation of this
score has been described previously.23 The men were asked
about drinking frequency (none, occasional or special
occasions, weekend, and daily drinkers) and were asked to
provide estimated weekly intake. Based on the combined
information of drinking frequency and reported weekly
estimate, the men were classified into five groups: none;
occasional (<1 U/wk), light (1–15 U/wk), moderate (16–42
U/wk), and heavy (>42 U/wk).24 Occupational social class
was split into three groups (manual, nonmanual, armed
forces) based on the longest-held occupation coded using
the Registrar General’s classification. At baseline, partici-
pants were classified as having prevalent myocardial
infarction (MI) or prevalent stroke if they had a previous
diagnosis of these events according to medical records or
self-report. Plasma concentrations of C-reactive protein
(CRP), D-dimer, and von Willebrand factor (vWF) were
also measured as detailed elsewhere.25
Follow-Up
Participants were followed prospectively for CVD and
all-cause mortality from re-examination (1998–2000) to
June 2010. Follow-up has been achieved for 98% of the
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cohort.26 Information on death was collected through
National Health Service Central Registers (death certifi-
cates coded using the International Classification of Dis-
eases, Ninth Revision (ICD-9)). Fatal MI was defined as
ICD-9 codes 410–414, fatal stroke as ICD-9 codes 430–
438, and fatal CVD as ICD-9 codes 390–459. A nonfatal
MI was diagnosed according to World Health Organiza-
tion criteria.27 Nonfatal stroke events were those that pro-
duced a neurological deficit that was present for more
than 24 hours. Evidence regarding nonfatal MI and nonfa-
tal stroke was obtained according to ongoing general prac-
titioner reports and biennial medical record reviews.17 The
four outcome measures assessed in this study were coro-
nary heart disease (CHD) events (fatal or nonfatal MI),
CVD events (nonfatal MI, nonfatal stroke, or fatal CVD),
CVD mortality, and all-cause mortality.
Statistical Analysis
Of the 4,252 men attending re-examination, 69 with pre-
valent heart failure were excluded because of exceptionally
high mortality rates and the strong association between
heart failure and weight loss. In addition, 71 men with
missing MAMC or WC data and one who died on the
examination day were excluded, leaving 4,111 for analy-
ses. Comparative analysis was performed in 4,045 individ-
uals with BIA measurements, classifying sarcopenic obesity
using FMI and FFMI. CRP and D-dimer were log-trans-
formed because distributions were highly skewed. Associa-
tions between sarcopenic obesity groups and outcome
measures were examined using Cox proportional hazards
regression, comparing the sarcopenic, obese, and sarcope-
nic obese groups with the optimal reference group. Models
were adjusted for potential confounders and mediators in
a sequential manner, including age (Model 1); lifestyle
variables (smoking status, alcohol intake, physical activity,
and occupational social class; Model 2); prevalent MI or
stroke and cardiovascular risk factors (Model 3); markers
of inflammation, coagulation, and endothelial dysfunction
(Model 4); and weight loss (Model 5). Smoking status,
alcohol intake, occupational social class, physical activity,
prevalent MI, prevalent stroke, and weight loss were fitted
as categorical variables. Age, high-density lipoprotein cho-
lesterol (HDL-C), systolic blood pressure (SBP), FEV1,
CRP, D-dimer, and vWF were fitted as continuous vari-
ables. An interaction between sarcopenia and obesity was
tested for using a Cox proportional hazards model with an
interaction term between obesity and sarcopenia (fitted as
binary variables using the cut-points described earlier).
Sensitivity analysis excluding men with prevalent MI
or stroke (n = 640) was also conducted, but this made no
real difference to the direction or magnitude of observed
associations (results not shown). Prevalent cases of MI and
stroke were therefore included in the analysis, and preva-
lent MI and prevalent stroke were added as covariates to
the models. All statistical analyses were performed using
Stata 12.0 (Stata Corp, College Station, TX).
RESULTS
There were 1,314 deaths during the mean follow-up of
11.3 years, 518 of which were attributed to cardiovascular
causes; 458 men experienced a CHD event, and 852 expe-
rienced a CVD event. One thousand four hundred ninety
(36.2%) men were classified as having optimal WC and
MAMC, 1,443 (35.1%) were sarcopenic only, 983
(23.9%) were obese only, and 195 (4.7%) were sarcopenic
obese. Participants had a mean age of 68.7  5.5 years,
WC of 97.1  10.4 cm, BMI of 26.9  3.6 kg/m2, and
MAMC of 26.5  2.3 cm. Table 1 shows the baseline
characteristics of participants according to sarcopenic
obesity groups. The optimal reference group was generally
at the lowest risk of CVD, and the sarcopenic obese group
had the highest proportion of inactive individuals; the
highest mean CRP, D-dimer, and vWF levels; and the low-
est mean FEV1. The sarcopenic group had the greatest pro-
portion of current smokers and self-reported weight loss
and the highest mean HDL-C. The obese group had the
highest proportion of heavy drinkers, the highest mean
SBP, and the lowest mean HDL-C.
Unadjusted rates of all outcomes (CHD events, CVD
events, CVD mortality, all-cause mortality) were lowest in
the optimal reference group and highest in the sarcopenic
obese group, but the difference between these two groups
was nonsignificant for CHD events (Figure 1). Table 2
shows adjusted hazard ratios (HRs) for CHD events,
CVD events, CVD mortality, and all-cause mortality by
sarcopenic obesity groups. In the age-adjusted model,
only the obese group had a significantly greater risk of
CHD events than the optimal reference group, but this
became nonsignificant after adjusting for lifestyle vari-
ables. Sarcopenia, obesity, and sarcopenic obesity were
associated with a significantly higher risk of CVD events
than in the optimal reference group, but these associations
became nonsignificant after adjustment for lifestyle
variables.
Sarcopenic men and obese men had a higher CVD
mortality risk than men with optimal WC and MAMC,
and the risk was greatest in the sarcopenic obese men,
adjusting for age. After adjustment for lifestyle variables,
the greater risks in sarcopenic and obese men remained
significant, but the greater risk in sarcopenic obese men
was no longer significant. Additional adjustment for preva-
lent MI, prevalent stroke, HDL-C, SBP, and FEV1 resulted
in a nonsignificant association in the obese group. Further
adjustment for CRP, D-dimer, and vWF in the sarcope-
nic group attenuated the associations, which became
nonsignificant.
Sarcopenic and obese men had significantly greater
risk of all-cause mortality after adjustment for lifestyle
variables, with the highest risk seen in sarcopenic obese
men (sarcopenic, HR = 1.41, 95% CI = 1.22–1.63;
obese, HR = 1.21, 95% CI = 1.03–1.42; sarcopenic obese,
HR = 1.72, 95% CI = 1.35–2.18). The greater mortality
associated with sarcopenia and sarcopenic obesity (but not
obesity) remained after adjustment for prevalent MI, pre-
valent stroke, HDL-C, SBP, FEV1, CRP, D-dimer, vWF,
and weight loss (sarcopenic, HR = 1.34, 95% CI = 1.15–
1.57; sarcopenic obese, HR = 1.44, 95% CI = 1.10–1.90).
There was no evidence of interaction between sarcopenia
and obesity for any of the outcomes.
Risk of non-CVD mortality was significantly greater
in sarcopenic men (HR = 1.39, 95% CI = 1.14–1.70) and
sarcopenic obese men (HR = 1.73, 95% CI = 1.23–2.42)
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than in the optimal group, even after adjustment, but a
significantly greater risk in non-CVD mortality was not
seen in the obese group.
Table 3 shows adjusted HRs for outcomes according to
sarcopenic obesity groups using the alternative classification
of FFMI and FMI measurements. After adjustment for
Table 1. Baseline Characteristics of British Regional Heart Study Participants According to Sarcopenic Obesity
Groups (Defined According to Waist Circumference (WC) and Midarm Muscle Circumference (MAMC))
Characteristic
Sarcopenic Obesity Groupsa
P-Valueb
Optimal,
n = 1,490
(36.2%)
Sarcopenic,
n = 1,443
(35.1%)
Obese,
n = 983
(23.9%)
Sarcopenic
Obese,
n = 195 (4.7%)
Sociodemographic and lifestyle variables
Age, meanSD 67.6  5.3 70.0  5.6 68.2  5.3 70.3  5.5 .08
Current smokers, n (%) 157 (10.5) 240 (16.7) 101 (10.3) 26 (13.5) <.001
Heavy drinkers, n (%) 28 (1.9) 44 (3.1) 37 (3.9) 6 (3.2) .03
Physically inactive, n (%) 86 (6.0) 154 (11.0) 151 (15.9) 37 (20.2) <.001
Manual workers, n (%) 691 (46.5) 725 (50.4) 547 (55.7) 113 (58.0) <.001
Anthropometrics
WC, cm, mean  SD 94.2  5.5 90.0  7.6 109.4  6.7 108.6  6.9 <.001
Body mass index, kg/m2, mean  SD 26.4  2.0 24.2  2.5 31.0  3.1 29.2  2.9 <.001
MAMC, cm, mean  SD 27.6  1.3 24.2  1.3 28.6  1.8 24.7  1.0 <.001
Weight loss in past 3 years, n (%) 194 (13.7) 234 (17.6) 137 (14.9) 27 (15.3) .04
Biological measures
High-density lipoprotein, mm, mean  SD 1.3  0.3 1.4  0.4 1.2  0.3 1.3  0.3 <.001
Systolic blood pressure, mmHg,
mean  SD
148.3  23.4 148.0  25.6 152.2  23.3 149.5  23.2 .001
Forced expiratory volume in 1 second,
L, mean  SD
2.7  0.6 2.5  0.7 2.5  0.6 2.3  0.7 .01
C-reactive protein, mg/L, geometric
mean (IQR)c
1.4 (0.7–2.7) 1.6 (0.7–3.4) 2.3 (1.2–4.0) 2.8 (1.4–5.6) <.001
D-dimer, ng/mL, geometric mean (IQR)c 76.0 (45.0–114.0) 90.6 (51.0–141.0) 83.2 (50.0–121.0) 106.1 (59.5–155.0) .003
von Willebrand factor, IU/dL, mean  SD 132.0  43.2 143.0  46.6 141.9  45.9 156.9  53.0 <.001
SD = Standard Deviation; IQR = Interquartile Range.
aOptimal (WC ≤ 102 cm, MAMC > 25.9 cm); sarcopenic (WC ≤ 102 cm, MAMC ≤ 25.9 cm); obese (WC > 102 cm, MAMC > 25.9 cm); sarcopenic
obese (WC > 102 cm, MAMC ≤ 25.9 cm).
bP-Value for difference between groups (x2 for percentages; analysis of variance for means).
c Log-transformed values.
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Figure 1. Unadjusted rates of coronary heart disease (CHD) events, cardiovascular disease (CVD) events, CVD mortality, and
all-cause mortality (per 1,000 person-years; 95% confidence interval) according to sarcopenic obesity groups (defined according
to waist circumference (WC) and midarm muscle circumference (MAMC)). Optimal (WC ≤ 102 cm, MAMC > 25.9 cm), sarco-
penic (WC ≤ 102 cm, MAMC ≤ 25.9 cm), obese (WC > 102 cm, MAMC > 25.9 cm), sarcopenic obese (WC > 102 cm,
MAMC ≤ 25.9 cm).
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lifestyle variables (Model 2) there was no significantly
greater risk of any outcomes in the sarcopenic, obese, or sar-
copenic obese group than in the optimal reference group.
DISCUSSION
The current study investigated the effects of sarcopenia,
obesity, and sarcopenic obesity on CVD and mortality risk
in a prospective cohort of older men, adding to the limited
literature in this area. Sarcopenic obesity was classified
using two methods, and the role of a wide range of poten-
tial risk factors, including inflammatory and hemostatic
markers, that had not previously been explored was exam-
ined. Sarcopenia (MAMC ≤ 25.9 cm) and obesity (WC >
102 cm) were associated with CVD mortality and all-cause
mortality risk. Sarcopenic obese men had the highest risk
Table 2. Coronary Heart Disease (CHD) Events, Cardiovascular Disease (CVD) Events, CVD Mortality, and
All-Cause Mortality According to Sarcopenic Obesity Groups (Defined According to Waist Circumference (WC)
and Midarm Muscle Circumference (MAMC))
Sarcopenic Obesity Groupsa
P-Value
(sarcopenia x Obesity
Interaction)
Optimal Sarcopenic Obese Sarcopenic obese
HR HR (95% CI) HR (95% CI) HR (95% CI)
CHD events (n = 458) Model 1 1.00 1.22 (0.97–1.53) 1.33 (1.04–1.70)b 1.37 (0.90–2.08) .50
Model 2 1.00 1.09 (0.86–1.38) 1.19 (0.92–1.55) 1.11 (0.71–1.75) .55
CVD events (n = 852) Model 1 1.00 1.19 (1.01–1.41)b 1.30 (1.08–1.56)b 1.39 (1.02–1.89)b .55
Model 2 1.00 1.11 (0.93–1.32) 1.18 (0.98–1.43) 1.08 (0.77–1.52) .31
CVD mortality (n = 518) Model 1 1.00 1.48 (1.19–1.85)b 1.60 (1.25–2.03)b 1.79 (1.19–1.85)b .21
Model 2 1.00 1.35 (1.07–1.70)b 1.39 (1.07–1.80)b 1.38 (0.91–2.08) .20
Model 3 1.00 1.33 (1.04–1.70)b 1.18 (0.89–1.55) 1.29 (0.83–2.00) .44
Model 4 1.00 1.26 (0.98–1.61) 1.12 (0.84–1.48) 1.14 (0.73–1.79) .42
All-cause mortality
(n = 1314)
Model 1 1.00 1.54 (1.34–1.76)b 1.41 (1.21–1.64)b 2.09 (1.67–2.62)b .79
Model 2 1.00 1.41 (1.22–1.63)b 1.21 (1.03–1.42)b 1.72 (1.35–2.18)b .95
Model 3 1.00 1.37 (1.18–1.59)b 1.11 (0.93–1.32) 1.61 (1.25–2.08)b .70
Model 4 1.00 1.34 (1.15–1.56)b 1.07 (0.90–1.28) 1.49 (1.15–1.93)b .81
Model 5 1.00 1.34 (1.15–1.57)b 1.07 (0.89–1.28) 1.44 (1.10–1.90)b .96
CHD = Coronary Heart Disease; CVD = Cardiovascular Disease; HR = Hazard Ratio; MAMC = Midarm Muscle Circumference; WC = Waist Circumfer-
ence. Model 1: adjusted for age. Model 2: adjusted for model 1 + smoking, alcohol, occupational social class, physical activity. Model 3: adjusted for model
2 + prevalent MI, prevalent stroke, HDL, SBP, FEV1. Model 4: adjusted for model 3 + CRP, D-dimer, vWF. Model 5: adjusted for model 4 + weight loss.
a Optimal (WC ≤ 102 cm, MAMC > 25.9 cm); sarcopenic (WC ≤ 102 cm, MAMC ≤ 25.9 cm); obese (WC > 102 cm, MAMC > 25.9 cm); sarcopenic
obese (WC > 102 cm, MAMC ≤ 25.9 cm).
b P < .05.
Table 3. Coronary Heart Disease (CHD) Events, Cardiovascular Disease (CVD) Events, CVD Mortality, and
All-Cause Mortality According to Sarcopenic Obesity Groups (Defined According to Fat Mass Index (FMI) and
Fat-Free Mass Index (FFMI))
Sarcopenic Obesity Groupsa
P-Value
(sarcopenia x Obesity
Interaction)
Optimal Sarcopenic Obese
Sarcopenic
Obese
HR HR (95% CI) HR (95% CI) HR (95% CI)
Total, n (%) 1670 (41.3) 1190 (29.4) 756 (18.7) 429 (10.6)
CHD events (n = 450) Model 1 1.00 1.17 (0.94–1.46) 1.13 (0.87–1.48) 1.35 (1.00–1.83)b .92
Model 2 1.00 1.15 (0.91–1.45) 1.04 (0.79–1.38) 1.13 (0.82–1.56) .79
CVD events (n = 827) Model 1 1.00 1.05 (0.89–1.24) 1.10 (0.90–1.33) 1.21 (0.97–1.51) .77
Model 2 1.00 1.03 (0.87–1.22) 1.01 (0.82–1.24) 1.01 (0.79–1.29) .85
CVD mortality (n = 502) Model 1 1.00 1.18 (0.95–1.46) 1.43 (1.12–1.82)b 1.37 (1.02–1.82)b .29
Model 2 1.00 1.11 (0.89–1.39) 1.25 (0.96–1.62) 1.11 (0.81–1.53) .30
All-cause mortality
(n = 1288)
Model 1 1.00 1.19 (1.05–1.36)b 1.26 (1.08–1.47)b 1.18 (0.98–1.42) .05
Model 2 1.00 1.08 (0.94–1.24) 1.09 (0.92–1.27) 0.98 (0.80–1.20) .19
CHD = Coronary Heart Disease; CVD = Cardiovascular Disease; FFMI = Fat-Free Mass Index; FMI = Fat Mass Index; HR = Hazard Ratio. Model 1:
adjusted for age. Model 2: adjusted for model 1 + smoking, alcohol, occupational social class, physical activity.
a Cutoff for obesity (FMI > 28.7th percentile) corresponds to the WC > 102cm cutoff. Optimal (FMI ≤ 11.1 kg/m2, FFMI > 16.7 kg/m2); sarcopenic
(FMI ≤ 11.1 kg/m2, FFMI ≤ 16.7 kg/m2); obese (FMI > 11.1 kg/m2, FFMI > 16.7 kg/m2); sarcopenic obese (FMI > 11.1 kg/m2, FFMI ≤ 16.7 kg/m2)
b P < .05.
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of all-cause mortality but did not have an excess risk of
CVD mortality beyond that associated with sarcopenia or
obesity alone. Comparative analysis, using FFMI and FMI
measurements to classify sarcopenic obesity, found no sig-
nificant associations between sarcopenic obese groups and
any of the outcomes.
WC and MAMC Measurements
Sarcopenia, obesity, and sarcopenic obesity were not asso-
ciated with significantly greater risk of CHD events or
CVD events after adjustment for lifestyle variables,
although sarcopenia was associated with CVD mortality
even after adjustment for blood pressure and blood lipids.
This association was no longer significant after adjustment
for CRP, D-dimer, and vWF, suggesting that inflammation
explained this greater CVD mortality, which is consistent
with the finding that CRP is more strongly associated with
the risk of fatal vascular events than nonfatal vascular
events.28 Obesity was associated with greater risk of CVD
mortality, which was attenuated after adjustment for
established cardiovascular risk factors. The observed asso-
ciation between abdominal obesity and greater risk of
CVD mortality is consistent with a previous meta-analysis
in elderly adults.6 Cross-sectionally, sarcopenic obese men
had the least favorable cardiovascular risk profile, which is
consistent with other cross-sectional studies,29,30 but sarco-
penic obesity was not associated with greater CVD mortal-
ity risk after adjustment for lifestyle variables, perhaps
because of the small numbers in this group. The findings
of the current study are broadly consistent with those of a
prospective study of community-dwelling older men and
women (aged ≥65) that found that the risk of CHD and
CVD events was not significantly greater in the sarcopenic,
obese, or sarcopenic obese groups (as determined accord-
ing to WC and BIA-measured muscle mass) than in the
optimal group after adjustment for behavioral variables,15
although the prior study did not specifically examine CVD
mortality, which was associated with sarcopenia and obes-
ity in the current study. The authors of this aforemen-
tioned study implied that muscle strength rather than
muscle mass may be more important, because sarcopenic
obesity (defined using grip strength) was predictive of
greater risk of CVD events.
Sarcopenia was associated with greater all-cause mor-
tality, which was independent of lifestyle and cardiovascu-
lar risk markers. This is consistent with previous
prospective studies in older adults that have found associa-
tions between various measures of low muscle mass and
greater mortality risk.7–9,11 Although inflammation is
strongly related to sarcopenia and all-cause mortality,31,32
these previous studies did not assess the contributing role
of CRP; the current study showed that inflammation did
not explain the association between sarcopenia and
mortality. Obesity was associated with greater all-cause
mortality, independent of lifestyle variables, but the associ-
ation disappeared after adjustment for established cardio-
vascular risk factors. Despite obesity being a strong risk
factor for mortality, some previous studies have shown
that overweight and obesity are not as adverse in elderly
populations.5,33–35 The results of the current study are also
consistent with a prospective study suggesting that muscle
mass (measured using midupper arm circumference) may
have a stronger association with mortality than obesity
(measured using BMI).11 Sarcopenic obese older men had
a higher risk of all-cause mortality than the optimal refer-
ence group after adjustment for lifestyle variables. The
observed association between sarcopenic obesity and mor-
tality diminished slightly after adjustment for potential
mediators (blood pressure, blood lipids, and inflamma-
tion), but significantly greater risk remained, suggesting
that cardiovascular and inflammatory risk markers only
partially explain the relationship between sarcopenic obes-
ity and mortality. Moreover, sarcopenic obesity was more
strongly related to non-CVD mortality, independent of
inflammation, than CVD mortality. Despite the sarcopenic
obese group having the highest risk of mortality, there was
no evidence of interaction between sarcopenia and obesity,
suggesting that the presence of obesity does not modify the
effect of sarcopenia (or equivalently, that the presence of
sarcopenia not modify the effect of obesity).
This study confirms initial work performed in this
cohort suggesting that the combined use of WC and
MAMC provides simple anthropometric body composition
measures to assess the risk of mortality in older men.10
The current study has almost double the follow-up (period
extended from 6 to 11 years) and includes additional out-
comes (CHD events, CVD events, and CVD mortality).
The results are consistent with the limited evidence from
prospective studies on the association between sarcopenic
obesity and mortality in disease-specific states13,14 and
extend findings to a large sample drawn from an older
general population. The current study found a direction of
association between sarcopenic obesity and all-cause mor-
tality similar to that of a previous study with longer
follow-up in which overweight men below the first tertile
of grip strength had 1.39 times the mortality risk as
normal-weight men above the third tertile.36
Fat Mass and Fat-Free Mass Measurements
Using FMI and FFMI measurements to classify sarcopenic
obesity, there was no significant difference in risk of out-
comes between the sarcopenic, obese, or sarcopenic obese
groups and the optimal reference group after adjustment
for behavioral variables. This supports previous research
in this cohort suggesting that a composite anthropometric
measure of MAMC and WC is more effective in predict-
ing all-cause mortality than measures of FFMI and
FMI.10 These null results are also consistent with a previ-
ous study showing that the risk of CHD and CVD events
was not higher in sarcopenic or sarcopenic obese individu-
als using BIA-measured muscle mass.15 The use of BIA to
assess FFM in elderly adults can be inaccurate princi-
pally because of the variability that exists in FFM hydra-
tion.37,38 This may explain the observed lack of
association between BIA-defined sarcopenic obesity and
outcomes seen here.
Strengths and Limitations
The strengths of this study were that it was a large
population-based cohort with high follow-up levels and
that two different muscle mass measures were compared,
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although older men, predominantly of white European eth-
nic origin, were investigated, so findings may not be gener-
alizable to women and nonwhite groups. Although all
study outcomes were based on objective measurements,
self-reported variables may have been subject to misclassifi-
cation. Residual confounding may have existed, for exam-
ple in the case of physical activity, which was measured
subjectively. Observed associations between sarcopenic
obesity groups and outcomes may have been further atten-
uated if objective measures of physical activity had been
available. A direct measure of adiposity or muscle mass
such as computed tomographic scanning or magnetic reso-
nance imaging was not available, but such expensive, time-
consuming measures are rarely available in primary care
settings, and MAMC and WC represent a practical alterna-
tive. The cutoff used for the lowest two-fifths of MAMC
(≤25.9 cm) was comparable with that used in another pop-
ulation-based study of men (aged ≥80) that used a cutoff
below the first tertile of 21.1 cm.9 WC has also been
shown to be the anthropometric variable that best corre-
lates with adiposity stores as measured by magnetic reso-
nance imaging, in men.39 Using imprecise measurements of
adiposity and muscle mass may have attenuated the
strength of associations observed between sarcopenic obes-
ity groups and outcomes. The European Working Group
on Sarcopenia in Older People has suggested defining sar-
copenia using muscle mass and function (strength and per-
formance).4 Measures of muscle function were not
available here, so findings are applicable to sarcopenic
obesity as defined by muscle mass but not function.
In conclusion, sarcopenia and abdominal obesity are
associated with all-cause mortality, with the highest risk in
sarcopenic obese men. Sarcopenia and sarcopenic obesity,
but not obesity on its own, were associated with greater
all-cause mortality independent of CVD risk factors,
inflammation, and weight loss. No association was found
between sarcopenia and obesity and CHD and CVD
events, but sarcopenia and obesity were associated with
greater CVD mortality, largely because of their associa-
tions with blood pressure, blood lipids and inflammation.
Efforts to promote healthy aging should focus on prevent-
ing obesity and maintaining muscle mass.
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